Revisi per 27 Oktober 2024 04.29 sunting Muhammad Anas Sidik (bicara \| kontrib) 23.606 suntingan ←Membuat halaman berisi '{{Infobox drug \| Verifiedfields = changed \| Watchedfields = changed \| verifiedrevid = 464390579 \| image = Silodosin Structural Formula V.1.svg \| width = \| alt = \| caption = <!-- Clinical data --> \| pronounce = \| tradename = Urief, Rapaflo, Silodyx, others \| Drugs.com = {{Drugs.com\|monograph\|silodosin}} \| MedlinePlus = a609002 \| licence_US = <!-- FDA may use generic or brand name (generic name preferred) --> \| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --...' Tag: kemungkinan perlu dirapikan Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan		Revisi per 27 Oktober 2024 04.35 sunting balikkan Muhammad Anas Sidik (bicara \| kontrib) 23.606 suntingan Tidak ada ringkasan suntingan Tag: halaman dengan galat kutipan Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan Revisi selanjutnya →
Baris 8: \| caption = <!-- Clinical data --> \| pronounce = \| tradename = Urief, Rapaflo, Silodyx, ~~others~~dll \| Drugs.com = {{Drugs.com\|monograph\|silodosin}} \| MedlinePlus = a609002 Baris 15: \| pregnancy_AU_comment = \| pregnancy_category = \| routes_of_administration = [[Oral ~~administration\|By mouth]]~~ \| class = [[Alpha-1 blocker\|α<sub>1</sub> blocker]] \| ATC_prefix = G04 Baris 41: <!-- Pharmacokinetic data -->\| bioavailability = 32% \| protein_bound = 96.,6% \| metabolism = ~~[[Liver]]~~Glukuronidasi ~~[[glucuronidation]]~~hati ([[dimediasi UGT2B7~~]]-mediated~~); ~~also~~juga ~~minor~~keterlibatan [[CYP3A4]] ~~involvement~~minor \| metabolites = \| onset = \| elimination_half-life = 13±8 ~~hours~~jam{{citation needed\|date=January 2020}} \| duration_of_action = \| excretion = 33.,5% [[~~Kidney~~Ginjal]],; 54.,9% ~~fecal~~feses <!-- Identifiers -->\| CAS_number_Ref = {{cascite\|changed\|??}} Baris 68: \| synonyms = KAD-3213, KMD-3213 <!-- Chemical and physical data -->\| IUPAC_name = 1-(3-~~hydroxypropyl~~hidroksipropil)-5-[(2''R'')-({2-[2-[2-(2,2,2-~~trifluoroethoxy~~trifluoroetoksi)~~phenoxy~~fenoksi]~~ethyl~~etil}amino)~~propyl~~propil]~~indoline~~indolina-7-~~carboxamide~~karboksamida \| C = 25 \| H = 32 Baris 92: }} '''Silodosin''' adalah obat untuk pengobatan simtomatik [[hiperplasia prostat jinak~~.[4~~][5]. Obat ini bertindak sebagai antagonis reseptor adrenergik alfa-1.~~[4][5]~~<ref name="Rapaflo FDA label" /><ref name="Silodyx EPAR" /> Efek samping yang paling umum adalah pengurangan jumlah air mani yang dikeluarkan saat ejakulasi.~~[5]~~<ref name="Silodyx EPAR" /> ==Sejarah== ==Kegunaan dalam medis==

Silodosin: Perbedaan antara revisi